ID   SK-OV-3
AC   CVCL_0532
SY   SKOV-3; SK-OV3; SK.OV.3; SKOV3; Skov3; SKO3; SKOV3 (S)
DR   BTO; BTO:0000948
DR   CLO; CLO_0009063
DR   EFO; EFO_0002340
DR   MCCL; MCC:0000431
DR   CLDB; cl4354
DR   CLDB; cl4355
DR   CLDB; cl4356
DR   AddexBio; C0017008/5024
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-77
DR   BioSample; SAMN03471310
DR   BioSample; SAMN05292466
DR   BioSample; SAMN10987874
DR   cancercelllines; CVCL_0532
DR   CCRID; 1101HUM-PUMC000027
DR   CCRID; 3101HUMTCHu185
DR   CCRID; 4201HUM-CCTCC00114
DR   CCTCC; GDC0114
DR   Cell_Model_Passport; SIDM00079
DR   ChEMBL-Cells; CHEMBL3307746
DR   ChEMBL-Targets; CHEMBL614925
DR   CLS; 300342
DR   Cosmic; 687925
DR   Cosmic; 688110
DR   Cosmic; 755846
DR   Cosmic; 809115
DR   Cosmic; 844348
DR   Cosmic; 849611
DR   Cosmic; 875858
DR   Cosmic; 897436
DR   Cosmic; 897739
DR   Cosmic; 905959
DR   Cosmic; 906578
DR   Cosmic; 920359
DR   Cosmic; 923106
DR   Cosmic; 924150
DR   Cosmic; 927563
DR   Cosmic; 932983
DR   Cosmic; 947358
DR   Cosmic; 948289
DR   Cosmic; 949228
DR   Cosmic; 991320
DR   Cosmic; 1044243
DR   Cosmic; 1057759
DR   Cosmic; 1066218
DR   Cosmic; 1070900
DR   Cosmic; 1071897
DR   Cosmic; 1092635
DR   Cosmic; 1093556
DR   Cosmic; 1102817
DR   Cosmic; 1113276
DR   Cosmic; 1129658
DR   Cosmic; 1139226
DR   Cosmic; 1175886
DR   Cosmic; 1176622
DR   Cosmic; 1305333
DR   Cosmic; 1312193
DR   Cosmic; 1312359
DR   Cosmic; 1436037
DR   Cosmic; 1482526
DR   Cosmic; 1523762
DR   Cosmic; 1524361
DR   Cosmic; 1707561
DR   Cosmic; 1708388
DR   Cosmic; 1709249
DR   Cosmic; 1998478
DR   Cosmic; 2301586
DR   Cosmic; 2464670
DR   Cosmic; 2560252
DR   Cosmic; 2582807
DR   Cosmic; 2668296
DR   Cosmic-CLP; 905959
DR   DepMap; ACH-000811
DR   ECACC; 91091004
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 905959
DR   GEO; GSM2110
DR   GEO; GSM50223
DR   GEO; GSM50287
DR   GEO; GSM183338
DR   GEO; GSM183341
DR   GEO; GSM274701
DR   GEO; GSM313702
DR   GEO; GSM459638
DR   GEO; GSM459643
DR   GEO; GSM459644
DR   GEO; GSM459645
DR   GEO; GSM659405
DR   GEO; GSM711713
DR   GEO; GSM743478
DR   GEO; GSM743500
DR   GEO; GSM750833
DR   GEO; GSM784565
DR   GEO; GSM799368
DR   GEO; GSM799431
DR   GEO; GSM827322
DR   GEO; GSM847159
DR   GEO; GSM851940
DR   GEO; GSM887598
DR   GEO; GSM888681
DR   GEO; GSM1001423
DR   GEO; GSM1001424
DR   GEO; GSM1001486
DR   GEO; GSM1153439
DR   GEO; GSM1181272
DR   GEO; GSM1181301
DR   GEO; GSM1291150
DR   GEO; GSM1340593
DR   GEO; GSM1374883
DR   GEO; GSM1670455
DR   GEO; GSM2124684
DR   GEO; GSM2475005
DR   IARC_TP53; 21123
DR   ICLC; HTL01014
DR   IGRhCellID; SKOV3
DR   IZSLER; BS TCL 84
DR   KCB; KCB 200810YJ
DR   KCLB; 30077
DR   LiGeA; CCLE_824
DR   LINCS_HMS; 50044
DR   LINCS_LDP; LCL-1517
DR   Lonza; 133
DR   NCBI_Iran; C209
DR   NCI-DTP; SK-OV-3
DR   PharmacoDB; SKOV3_1411_2019
DR   PRIDE; PXD001402
DR   PRIDE; PXD005940
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   PRIDE; PXD007615
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0532
DR   PubChem_Cell_line; CVCL_0532
DR   SKY/M-FISH/CGH; 1438
DR   Wikidata; Q50432263
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=1423261;
RX   PubMed=1892748;
RX   PubMed=2041050;
RX   PubMed=2653399;
RX   PubMed=3335022;
RX   PubMed=3518877;
RX   PubMed=3804493;
RX   PubMed=4016745;
RX   PubMed=6582512;
RX   PubMed=7459858;
RX   PubMed=7718330;
RX   PubMed=8557231;
RX   PubMed=9041185;
RX   PubMed=9554442;
RX   PubMed=9698466;
RX   PubMed=10318951;
RX   PubMed=10700174;
RX   PubMed=10972993;
RX   PubMed=11416159;
RX   PubMed=11565033;
RX   PubMed=11789735;
RX   PubMed=11793438;
RX   PubMed=12080474;
RX   PubMed=12417041;
RX   PubMed=12960427;
RX   PubMed=15748285;
RX   PubMed=16380993;
RX   PubMed=17088437;
RX   PubMed=17726699;
RX   PubMed=19372543;
RX   PubMed=20164919;
RX   PubMed=20204287;
RX   PubMed=20215515;
RX   PubMed=21912889;
RX   PubMed=22068913;
RX   PubMed=22328975;
RX   PubMed=22336246;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22585861;
RX   PubMed=22628656;
RX   PubMed=22705003;
RX   PubMed=22710073;
RX   PubMed=23415752;
RX   PubMed=23839242;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24023729;
RX   PubMed=24279929;
RX   PubMed=24434149;
RX   PubMed=24670534;
RX   PubMed=25230021;
RX   PubMed=25485619;
RX   PubMed=25846456;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26169745;
RX   PubMed=26589293;
RX   PubMed=26668597;
RX   PubMed=26925792;
RX   PubMed=27235858;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=28273451;
RX   PubMed=30485824;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=32612269;
RX   PubMed=33519462;
RX   PubMed=35839778;
WW   https://en.wikipedia.org/wiki/SK-OV-3
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://www.synapse.org/#!Synapse:syn31544449
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=27
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=SK-OV-3
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/s/cell-lines-detail-19.html
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/human-ovarian-cell-line-sk-ov-3
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: JFCR39 cancer cell line panel.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI-60 cancer cell line panel.
CC   Part of: OCCP ovarian cancer cell line panel.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-528.
CC   Population: Caucasian.
CC   Doubling time: 44 hours (PubMed=7718330); 19 hours (PubMed=2653399); 28 +- 2 hours (PubMed=3804493); 28.8 hours (PubMed=4016745); 75 hours (PubMed=25984343); 48.7 hours (NCI-DTP=SK-OV-3); ~35 hours (PBCF); 33.29 hours (GrayJW panel).
CC   HLA typing: A*03,68; B*18,35; C*04,05; DPB1*02:01:02,04:01; DQB1*02:01,05:01:01; DRB1*01,03:01:01 (PubMed=15748285).
CC   HLA typing: A*03:01,68:01; B*18:01,35:01; C*04:01,05:01 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (PubMed=11565033; PubMed=25846456).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=17088437; PubMed=22705003; PubMed=25846456; PubMed=28273451).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (PubMed=17088437; PubMed=20204287).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Exosome proteome analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: Genome sequenced.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.52%; Native American=0%; East Asian, North=1.76%; East Asian, South=0%; South Asian=1.14%; European, North=59.05%; European, South=36.53% (PubMed=30894373).
CC   Misspelling: SCOV-3; Note=Occasionally.
CC   Misspelling: SCOV3; Note=Occasionally.
CC   Misspelling: SKVO3; Note=Occasionally.
CC   Discontinued: ICLC; HTL01014; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; KCLB; PubMed=11416159; PubMed=19372543; PubMed=25230021; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 8,11
ST   D16S539: 12
ST   D18S51: 16,17 (PubMed=19372543; PubMed=25230021_ECACC_version; PubMed=25877200)
ST   D18S51: 16,17,18 (CCRID; CLS; PubMed=11416159)
ST   D18S51: 16,18 (PubMed=25230021_academic_lab_version)
ST   D19S433: 14,14.2
ST   D21S11: 30,31,31.2 (CLS; PubMed=11416159; PubMed=30485824)
ST   D21S11: 30,31.2 (CCRID; PubMed=19372543; PubMed=25230021; PubMed=25877200)
ST   D2S1338: 18,23
ST   D3S1358: 13,14 (PubMed=19372543)
ST   D3S1358: 14 (CCRID; CLS; PubMed=25230021; PubMed=25877200)
ST   D5S818: 11
ST   D7S820: 13,14
ST   D8S1179: 14,15
ST   FGA: 23,24,25 (PubMed=25230021_ECACC_version)
ST   FGA: 24,25 (CCRID; KCLB; PubMed=25230021_academic_lab_version; PubMed=25877200)
ST   FGA: 24,25,26 (CLS; PubMed=11416159)
ST   Penta D: 12,13
ST   Penta E: 5,13
ST   TH01: 9,9.3
ST   TPOX: 8,11
ST   vWA: 17 (PubMed=25230021_acedemic_version)
ST   vWA: 17,18 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; KCLB; PubMed=11416159; PubMed=25230021_ECACC_version; PubMed=25877200; PubMed=30485824)
ST   vWA: 18 (PubMed=19372543)
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 44
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=1423261;
RA   Mistry P., Kelland L.R., Loh S.Y., Abel G., Murrer B.A., Harrap K.R.;
RT   "Comparison of cellular accumulation and cytotoxicity of cisplatin
RT   with that of tetraplatin and
RT   amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human
RT   ovarian carcinoma cell lines.";
RL   Cancer Res. 52:6188-6193(1992).
//
RX   PubMed=1892748; DOI=10.1038/bjc.1991.279;
RA   Mistry P., Kelland L.R., Abel G., Sidhar S., Harrap K.R.;
RT   "The relationships between glutathione, glutathione-S-transferase and
RT   cytotoxicity of platinum drugs and melphalan in eight human ovarian
RT   carcinoma cell lines.";
RL   Br. J. Cancer 64:215-220(1991).
//
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D.,
RA   Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A.,
RA   Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
//
RX   PubMed=2653399; DOI=10.1038/bjc.1989.108;
RA   Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P.,
RA   Harrap K.R.;
RT   "Biological properties of ten human ovarian carcinoma cell lines:
RT   calibration in vitro against four platinum complexes.";
RL   Br. J. Cancer 59:527-534(1989).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3804493; DOI=10.1002/ijc.2910390216;
RA   Hill B.T., Whelan R.D.H., Gibby E.M., Sheer D., Hosking L.K.,
RA   Shellard S.A., Rupniak H.T.;
RT   "Establishment and characterisation of three new human ovarian
RT   carcinoma cell lines and initial evaluation of their potential in
RT   experimental chemotherapy studies.";
RL   Int. J. Cancer 39:219-225(1987).
//
RX   PubMed=4016745;
RA   Buick R.N., Pullano R., Trent J.M.;
RT   "Comparative properties of five human ovarian adenocarcinoma cell
RT   lines.";
RL   Cancer Res. 45:3668-3676(1985).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H;
RA   Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J.,
RA   McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M.,
RA   van Zijl P.;
RT   "Resistance mechanisms determining the in vitro sensitivity to
RT   paclitaxel of tumour cells cultured from patients with ovarian
RT   cancer.";
RL   Eur. J. Cancer 31:230-237(1995).
//
RX   PubMed=8557231; DOI=10.1006/gyno.1996.0014;
RA   Skilling J.S., Squatrito R.C., Connor J.P., Niemann T., Buller R.E.;
RT   "p53 gene mutation analysis and antisense-mediated growth inhibition
RT   of human ovarian carcinoma cell lines.";
RL   Gynecol. Oncol. 60:72-80(1996).
//
RX   PubMed=9041185;
RA   Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.;
RT   "Increased platinum-DNA damage tolerance is associated with cisplatin
RT   resistance and cross-resistance to various chemotherapeutic agents in
RT   unrelated human ovarian cancer cell lines.";
RL   Cancer Res. 57:850-856(1997).
//
RX   PubMed=9554442; DOI=10.1093/jnci/90.8.597;
RA   Sabichi A.L., Hendricks D.T., Bober M.A., Birrer M.J.;
RT   "Retinoic acid receptor beta expression and growth inhibition of
RT   gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl)
RT   retinamide.";
RL   J. Natl. Cancer Inst. 90:597-605(1998).
//
RX   PubMed=9698466; DOI=10.1006/gyno.1998.5039;
RA   Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C.,
RA   Berchuck A., Futreal P.A.;
RT   "Mutation of the PTEN tumor suppressor gene is not a feature of
RT   ovarian cancers.";
RL   Gynecol. Oncol. 70:13-16(1998).
//
RX   PubMed=10318951; DOI=10.1073/pnas.96.10.5722;
RA   Lau K.-M., Mok S.C., Ho S.-M.;
RT   "Expression of human estrogen receptor-alpha and -beta, progesterone
RT   receptor, and androgen receptor mRNA in normal and malignant ovarian
RT   epithelial cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H;
RA   Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.;
RT   "Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon
RT   12 deletion variant in malignant human ovarian, prostate, and breast
RT   cancer cell lines.";
RL   Mol. Carcinog. 28:236-246(2000).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=11565033; DOI=10.1038/35095068;
RA   Moberg K.H., Bell D.W., Wahrer D.C.R., Haber D.A., Hariharan I.K.;
RT   "Archipelago regulates cyclin E levels in Drosophila and is mutated in
RT   human cancer cell lines.";
RL   Nature 413:311-316(2001).
//
RX   PubMed=11789735; DOI=10.1309/4NCM-QJ9W-QM0J-6QJE;
RA   Rhodes A., Jasani B., Couturier J., McKinley M.J., Morgan J.M.,
RA   Dodson A.R., Navabi H., Miller K.D., Balaton A.J.;
RT   "A formalin-fixed, paraffin-processed cell line standard for quality
RT   control of immunohistochemical assay of HER-2/neu expression in breast
RT   cancer.";
RL   Am. J. Clin. Pathol. 117:81-89(2002).
//
RX   PubMed=11793438; DOI=10.1002/gcc.1221;
RA   Rao P.H., Harris C.P., Lu X.-Y., Li X.-N., Mok S.C., Lau C.C.;
RT   "Multicolor spectral karyotyping of serous ovarian adenocarcinoma.";
RL   Genes Chromosomes Cancer 33:123-132(2002).
//
RX   PubMed=12080474; DOI=10.1038/sj.onc.1205542;
RA   Manzano R.G., Montuenga L.M., Dayton M., Dent P., Kinoshita I.,
RA   Vicent S., Gardner G.J., Nguyen P., Choi Y.-H., Trepel J.,
RA   Auersperg N., Birrer M.J.;
RT   "CL100 expression is down-regulated in advanced epithelial ovarian
RT   cancer and its re-expression decreases its malignant potential.";
RL   Oncogene 21:4435-4447(2002).
//
RX   PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x;
RA   Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M.,
RA   Takayama M., Sato A., Inazawa J.;
RT   "Differentially regulated genes as putative targets of amplifications
RT   at 20q in ovarian cancers.";
RL   Jpn. J. Cancer Res. 93:1114-1122(2002).
//
RX   PubMed=12960427; DOI=10.1091/mbc.E03-05-0279;
RA   Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G.,
RA   Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H.,
RA   Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J.,
RA   Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R.,
RA   van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O.,
RA   Sikic B.I.;
RT   "Gene expression patterns in ovarian carcinomas.";
RL   Mol. Biol. Cell 14:4376-4386(2003).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
//
RX   PubMed=16380993; DOI=10.1002/ijc.21671;
RA   Huang K.-C., Park D.C., Ng S.-K., Lee J.Y., Ni X., Ng W.-C.,
RA   Bandera C.A., Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.;
RT   "Selenium binding protein 1 in ovarian cancer.";
RL   Int. J. Cancer 118:2433-2440(2006).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=17726699; DOI=10.1002/gcc.20492;
RA   Buys T.P.H., Chari R., Lee E.H.L., Zhang M., MacAulay C., Lam S.,
RA   Lam W.L., Ling V.;
RT   "Genetic changes in the evolution of multidrug resistance for cultured
RT   human ovarian cancer cells.";
RL   Genes Chromosomes Cancer 46:1069-1079(2007).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20204287; DOI=10.3892/or_00000728;
RA   Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H.,
RA   Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.;
RT   "Radiosensitivity profiles from a panel of ovarian cancer cell lines
RT   exhibiting genetic alterations in p53 and disparate DNA-dependent
RT   protein kinase activities.";
RL   Oncol. Rep. 23:1021-1026(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21912889; DOI=10.1007/s10637-011-9744-z;
RA   Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A.,
RA   Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P.,
RA   Ding A., Baguley B.C.;
RT   "Therapeutic reactivation of mutant p53 protein by quinazoline
RT   derivatives.";
RL   Invest. New Drugs 30:2035-2045(2012).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170;
RA   Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D.,
RA   Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B.,
RA   Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A.,
RA   Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.;
RT   "Genomic complexity and AKT dependence in serous ovarian cancer.";
RL   Cancer Discov. 2:56-67(2012).
//
RX   PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017;
RA   Kong D., Yamori T.;
RT   "JFCR39, a panel of 39 human cancer cell lines, and its application in
RT   the discovery and development of anticancer drugs.";
RL   Bioorg. Med. Chem. 20:1947-1951(2012).
//
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011;
RA   Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M.,
RA   Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M.,
RA   Miyazaki K.;
RT   "Clinicopathologic and biological analysis of PIK3CA mutation in
RT   ovarian clear cell carcinoma.";
RL   Hum. Pathol. 43:2197-2206(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=23839242; DOI=10.1038/ncomms3126;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126.1-2126.10(2013).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L.,
RA   Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M.,
RA   Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:E72162-E72162(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
//
RX   PubMed=24434149; DOI=10.1016/j.bbrc.2013.12.070;
RA   Sinha A., Ignatchenko V., Ignatchenko A., Mejia-Guerrero S.,
RA   Kislinger T.;
RT   "In-depth proteomic analyses of ovarian cancer cell line exosomes
RT   reveals differential enrichment of functional categories compared to
RT   the NCI 60 proteome.";
RL   Biochem. Biophys. Res. Commun. 445:694-701(2014).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25846456; DOI=10.3892/ijo.2015.2951;
RA   Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M.,
RA   Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.;
RT   "Profiling of actionable gene alterations in ovarian cancer by
RT   targeted deep sequencing.";
RL   Int. J. Oncol. 46:2389-2398(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26169745; DOI=10.1186/s12967-015-0576-z;
RA   Halama A., Guerrouahen B.S., Pasquier J., Diboun I., Karoly E.D.,
RA   Suhre K., Rafii A.;
RT   "Metabolic signatures differentiate ovarian from colon cancer cell
RT   lines.";
RL   J. Transl. Med. 13:223.1-223.12(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26668597; DOI=10.3892/etm.2015.2836;
RA   Ruan Z.-Y., Liu J.-H., Kuang Y.-P.;
RT   "Isolation and characterization of side population cells from the
RT   human ovarian cancer cell line SK-OV-3.";
RL   Exp. Ther. Med. 10:2071-2078(2015).
//
RX   PubMed=26925792; DOI=10.4149/315_150930N510;
RA   Saczko J., Pilat J., Choromanska A., Rembialkowska N., Bar J.K.,
RA   Kaminska I., Zalewski J., Kulbacka J.;
RT   "The effectiveness of chemotherapy and electrochemotherapy on ovarian
RT   cell lines in vitro.";
RL   Neoplasma 63:450-455(2016).
//
RX   PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028;
RA   Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F.,
RA   Noonan A.M., Annunziata C.M.;
RT   "Characterization of ovarian cancer cell lines as in vivo models for
RT   preclinical studies.";
RL   Gynecol. Oncol. 142:332-340(2016).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-Awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=32612269; DOI=10.1038/s41598-020-67533-1;
RA   De Haven Brandon A., Box G., Hallsworth A., Court W., Matthews N.,
RA   Herodek B., Arteagabeitia A.B., Valenti M., Kirkin V.;
RT   "Identification of ovarian high-grade serous carcinoma cell lines that
RT   show estrogen-sensitive growth as xenografts in immunocompromised
RT   mice.";
RL   Sci. Rep. 10:10799-10799(2020).
//
RX   PubMed=33519462; DOI=10.3389/fphar.2020.600994;
RA   Zhang Y.-Q., Gan H.-Y., Zhao F., Ma X.-M., Xie X.-F., Huang R., Zhao J.;
RT   "CPEB4-promoted paclitaxel resistance in ovarian cancer in vitro
RT   relies on translational regulation of CSAG2.";
RL   Front. Pharmacol. 11:600994.1-600994.10(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//